What should be done to combat misinformation about health products?

Fake news Medicine Misinformation Public information Social media

Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
10 Nov 2023
Historique:
received: 05 10 2023
accepted: 10 10 2023
medline: 20 12 2023
pubmed: 20 12 2023
entrez: 19 12 2023
Statut: aheadofprint

Résumé

The increasing role of digital technology, social media, the wide range of channels and the volume of information, the role of medicine as a societal subject, public information that is insufficient and poorly suited to situations of uncertainty are all observations which led to the theme of this round table. After discussing the definition of disinformation, which is not limited to fake news, and talking about contributors who misinform, whether intentionally or not, the participants of this round table made nine recommendations (R) to combat disinformation about health products: create a collaborative platform, information/training on health products, a platform with five major characteristics, namely accessibility, flexibility, objectivity, transparency and independence, as well as media suited to the different targets (R1); promote basic knowledge on health products: education/training to restore the particularly poor image of medication, and teach the public how to use basic concepts appropriately (R2); improve communication to the public based on the observation that information is the main weapon against misinformation and entails, in particular, coordinating communication from the different institutions to make public information more audible, making institutional messages clearer, ensuring they are more factual and prioritising them (R3); know how to communicate using the correct codes and tools (R4), because, to be understood, the substance and the form are inseparable; develop research on communication in the field of health products (R5); acquire tools to identify and regulate as soon as possible (R6); keep check of content by developing critical thinking (R7); define quality criteria for information sources (R8); identify, assess and reference initiatives for the public that could be placed on the platform (R9).

Identifiants

pubmed: 38114387
pii: S0040-5957(23)00180-4
doi: 10.1016/j.therap.2023.11.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Auteurs

Joëlle Micallef (J)

Service de pharmacologie clinique et pharmacosurveillance, centre régional de pharmacovigilance, AP-HM, 13005 Marseille, France.

Hervé Maisonneuve (H)

Consultant, 75011 Paris, France. Electronic address: hervemaisonneuve@gmail.com.

Sophie Muller (S)

GSK, direction médicale, 92150 Rueil-Malmaison, France.

Mathieu Molimard (M)

Service de pharmacologie médicale, CHU de Bordeaux, 33000 Bordeaux, France.

Bernard Bégaud (B)

Collège santé, université de Bordeaux, 33076 Bordeaux cedex, France.

Sandrine Cabut (S)

Le Monde, 75013 Paris, France.

Mina Daban (M)

LMC France, 13000 Marseille, France.

Milou-Daniel Drici (MD)

Département de pharmacologie clinique, hôpital Pasteur, université Côte d'Azur, 06001 Nice, France.

Chantal Gatignol (C)

SG-CIPDR/MIVILUDES, 75008 Paris, France.

Anne Grumblat (A)

Pôle pharmaceutique, CHRU Jean-Minjoz, 25030 Besançon, France.

Catherine Guaspare-Cartron (C)

Groupe d'études des méthodes de l'analyse sociologique de la Sorbonne, 75017 Paris, France.

Bruno Lasserre (B)

Conseil d'État, 1, place du Palais-Royal, 75001 Paris, France.

Adel Mebarki (A)

Kap Code, 75002 Paris, France.

Catherine Pons (C)

Roche, unité pharmacovigilance, 92100 Boulogne-Billancourt, France.

Frédérique Prabonnaud (F)

Health care journalist, 75000 Paris, France.

Catherine Raynaud (C)

Pfizer, affaires publiques, 75014 Paris, France.

Olivier Saint-Lary (O)

Primary Care and Prevention Team, CESP, University Paris-Saclay, UVSQ, Inserm U1018, University Paris-Saclay, 94800 Villejuif, France.

Classifications MeSH